Hapreet Wasan discusses the tumor biology of pancreatic cancer, the potential role of the enzyme asparaginase in treating these cancers, and what advancements he hopes to see in the coming years.
Browsing: Taxonomy > Drug development
A new oral drug designed to improve efficacy of radiotherapy has been shown to be effective and safe as an adjunctive treatment for hard-to-treat cancers.
In a recent Phase II trial involving 35 patients with tumors with AKT mutations capivasertib, an AKT inhibitor, has demonstrated signs of effectiveness.
NICE has recommended the use of Lenvima® for untreated, advanced, unresectable hepatocellular carcinoma in adults.
The US FDA has approved Libtayo®, the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the USA.
NICE have approved dabrafenib plus trametinib for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults.
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
The prices of cancer drugs have skyrocketed in recent years, with Pharma companies being called out by both patients and Donald Trump. Who is to blame for this increase and how can we make cancer “more affordable”?
The China National Drug Administration have granted rapid approval of Alecensa® as a monotherapy treatment for patients with ALK-positive, advanced non-small cell lung cancer.